NCT04290481

Brief Summary

Congenital heart diseases are among the most common congenital anomalies and occur with an incidence of approximately 8ınd12 / 1,000 live births worldwide. This figure does not cover minor lesions such as bicuspid aortic valves and small atrial or ventricular septal defects. Most of these defects do not need treatment or treatment is needed after infancy. Other defects are severe and usually require early treatment in the neonatal period. Critical congenital heart disease is defined as structural heart defects that are associated with hypoxia in the neonatal period and have significant morbidity and mortality potential in early life. Critical congenital heart disease is estimated to be \~3 in 1000 live births. It is estimated that 50% of congenital heart diseases are detected by prenatal ultrasound. Even if a standard neonatal examination is performed, 13 to 55% of patients with critical congenital heart disease can be discharged from the hospital without being diagnosed. Screening of infants with non-invasive oxygen saturation measurement has been proposed as an adjunct to early detection of critical congenital heart disease. The American Academy of Pediatrics, the American Cardiology Foundation and the American Heart Association have targeted 7 specific lesions for the pulse oximetry screening protocol: truncus arteriosus, transposition of the great arteries, tricuspid atresia, tetralogy of Fallot, total pulmonary venous return anomaly, hypoplastic left heart syndrome and pulmonary atresia. The reference values of peripheral perfusion (PPI) index has been established for normal newborns between 1 and 120 h of age. Lower PPI values than 0.70 may indicate illness. Including cut-off values for PPI in pulse-oximetry screening for duct dependent congenital heart disease is a promising tool for improving the detection of critical congenital heart disease with duct-dependent systemic circulation. We aimed to investigate screening critical congenital heart disease and also to establish normal values of oxygen saturation and perfusion index at high altitude.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
501

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2018

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2018

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2019

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

February 27, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 2, 2020

Completed
Last Updated

March 2, 2020

Status Verified

February 1, 2020

Enrollment Period

8 months

First QC Date

February 27, 2020

Last Update Submit

February 27, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Establishing threshold values for critical congenital heart disease screening at high altitude

    We aim to explore whether oxygen saturation and perfusion index threshold values are different compared sea level or not.

    Postnatal 24-48 hours

Secondary Outcomes (1)

  • Establishing normal oxygen saturation and perfusion index values at high altitude

    Postnatal 24-48 hours

Interventions

Oxygen saturation and perfusion index values that are measured by pulse oximeter is used for screening critical congenital heart disease.

Eligibility Criteria

Age24 Hours - 48 Hours
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)
Sampling MethodProbability Sample
Study Population

Newborns with ≥34 weeks of gestational age

You may qualify if:

  • The newborns delivered in Ataturk University Hospital and ≥34 weeks of gestational age were eligible for the study.

You may not qualify if:

  • Outborn and premature babies (\<34 weeks) were not included. Babies with a prenatal diagnosis of congenital heart disease were excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ataturk University Medical Faculty

Erzurum, 25100, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Altitude Sickness

Interventions

Oxygen Saturation

Condition Hierarchy (Ancestors)

Respiration DisordersRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Metabolism

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Prof

Study Record Dates

First Submitted

February 27, 2020

First Posted

March 2, 2020

Study Start

June 1, 2018

Primary Completion

February 1, 2019

Study Completion

February 1, 2019

Last Updated

March 2, 2020

Record last verified: 2020-02

Data Sharing

IPD Sharing
Will not share

Locations